8th annual PREDiCT: Tumour Models London
2019-12-04 - 2019-12-06 | London, UK, United Kingdom
The 8th annual PREDiCT: Tumour Models London Summit will return this December with a new speaker faculty to help you benchmark your oncology model selection strategy and target validation. With the rise of immuno-oncology, model requirements, target validation and the importance of tumour micro-environment are key to clinical success. The 3-days summit will provide you with real world data from a selected model experts, including Merck, MedImmune, Takeda, Roche, AstraZeneca and more for practical insights.
To learn more about 8th annual PREDiCT: Tumour Models London and to register online, visit https://ter.li/6ge5rc

SMi’s Inaugural Conference: Respiratory Drug Delivery 2019
2019-12-05 - 2019-12-06 | Holiday Inn Kensington Forum, 97 Cromwell Road, London, SW7 4DN, United Kingdom
SMi are pleased to announce the launch of the Respiratory Drug Delivery conference as part of the newly branded Asthma and COPD series, which will be held in London on the 5th – 6th December 2019.

With the rising prevalence of respiratory disease such as Asthma, cystic fibrosis and COPD, this group of diseases are now amongst the leading cause of death, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe, yet little work is being done to reduce this high mortality rate.
Opportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However, the unmet medical needs of respiratory diseases sufferers remain.
Join us this year as SMi aim to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs, analysing the success of digital media devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design.
Benefits of attending:

Assessing how to transform disease management through drug combinations, devices and inhaled biological treatments
Evaluating respiratory device design development and novel technologies such as nanoparticle-based drug delivery
Exploring digital connective inhalation to improve patient centricity
Reviewing the challenges around the pricing and reimbursement of respiratory drug products

View the full agenda online: www.respiratorydrugdelivery.com/pharmajwl
Early bird rates:

BOOK BY 28TH JUNE AND SAVE £300
BOOK BY 30TH SEPTEMBER AND SAVE £100

SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #SMirespiratory
LinkedIn: follow our company page – search ‘SMi Pharma’
Contact
+44 (0) 20 7827 6088
hsidhu@smi-online.co.uk

BioFIT 2019
2019-12-10 - 2019-12-11 | MARSEILLE CHANOT, PALAIS DES CONGRÈS ET DES EXPOSITIONS Rond Point du Prado 13008 Marseille – FRANCE
EARLY-STAGE INNOVATIONS | ACADEMIA-INDUSTRY COLLABORATIONS | TECHNOLOGY TRANSFER | SEED INVESTMENT
With the highest attending rate of TTOs, research institutes and academia together with big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
WHY ATTEND BIOFIT?
Out of 1,000 BioFIT attendees, 1,000 deals have been generated. The breakdown in terms of nature of deals is the following:

35% of collaborative research projects
30% of licensing deals
15% of equity investment deals
20% of services deals

Estimate based on the measurement of 2015 and 2016 delegates’ outcomes

KEY FIGURES:

1,300+ delegates
800+ organisations
35+ countries represented
1,000 deals generated in 2017

INSIDE THE EVENT:

A business convention with pre-qualified one-to-one meetings
Identification of would-be CEOs
Conferences and roundtable discussions
Oral presentations of start-ups , licensing opportunities stemming from academia , service presentations
An exhibition area
Informal networking evenings

Please check out the different participants’ lists of the previous editions, as well as the list of this year’s edition >>here<<.
2018 Final programme
2019 Preliminary programme
Please feel free to widely share this document with your colleagues, network, partners…
BE PART OF THE EVENT:

Register now
Book your booth now

Website: www.biofit-event.com
Twitter: @BIOFIT_EVENT

Cell Therapy Analytical Development Summit
2019-12-10 - 2019-12-12 | Revere Hotel Boston Common 200 Stuart Street, Boston, MA, 02116, United States
The explosion in cell therapy development companies has fueled a need to develop well-characterized clinical products which has resulted in the call for robust and validated analytical assays now being louder and more important than ever before.
The inaugural Cell Therapy Analytical Development Summit brings you the leaders in CMC, analytics and process development to create standardized and automated analytical techniques and technologies for improved therapeutic characterization at scale.
Join over 100 of the world’s experts as we discuss how to navigate a murky regulatory landscape, robustly validate assays and advance the characterization of CAR-T and TCR cell therapy analytics to ensure safe, consistent and quality cell therapy products.

Get involved this December to:

Address the need to fully understand the mechanism of action of a cell therapy to develop representative potency assays
Assess methods to develop functional assays suitable for routine and timely testing to overcome operational constraints
Explore ways to develop non-destructive and non-invasive in-line analytics
Discuss current techniques being developed to standardize flow cytometry and explores ways to overcome batch effects
Highlight sources of variability in cell counting measurement such as environmental, procedural, analytical and instrumental, and techniques to minimize variability

Why do experts attend our cell therapy summits?
“Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring, and the Cell Therapy Summit is no different. We are energized by the discussions about cell therapy and its potential applications for bringing new therapies to patients in need.”
– Novartis
“This is a best in class and top summit in the cell therapy area which is an invaluable asset to both industries and academia.”
– University of Pennsylvania
Join us to ensure safe, consistent and quality cell therapy development with novel, scalable and automated analytical development assays.
To know more about Cell Therapy Analytical Development Summit click here

Pre-Filled Syringes and Injectable Drug Devices 2020
2020-01-15 - 2020-01-16 | Copthorne Tara Hotel, Kensington, Scarsdale Pl, Kensington, London, W8 5SY, United Kingdom
Assessing the regulatory environment and future of PFS design and development
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London on 15th and 16th January 2020.

As Europe’s leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.
With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year’s programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director – Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products , Senior Pharmaceutical Assessor and many more.
BENEFITS OF ATTENDING:

Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design
Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices
Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery
Assess industry case studies exploring how to overcome challenges of extractables and leachables

View the full agenda and speaker line-up online: www.pre-filled-syringes.com/pharmajwl
Plus, pre-conference workshop day will be taking place on 14th January in London:
Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards
Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH
Workshop C: Extractables and Leachables: Considerations for PFS Platforms
EARLY-BIRD RATES:

BOOK BY 30TH SEPTEMBER AND SAVE £400
BOOK BY 31ST OCTOBER AND SAVE £200
BOOK BY 29TH NOVEMBER AND SAVE £100

Registrations can be made on the event website at: www.pre-filled-syringes.com/pharmajwl
Chairs for 2019:

James Mellman, Device Manager, Novartis
Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers:

Abha Raveau-Violette, Device Manager, AstraZeneca
Amanda Matthews, Senior Director, Pfizer
Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT
Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson
Cinzia Rotella, Senior Materials Scientist, Sanofi
Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer
Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals
Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc
James Mellman, Device Manager, Novartis A G
Kewei Yang, Pharmaceutical Scientist, Roche
Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc
Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)
Matthew Nicolas, Investigator, GlaxoSmithKline
Nicolas Eon, Senior Global Product Manager, SCHOTT
Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH
Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences
Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
Follow us: @SMiPharm #PFSSMi

Disruptive Technologies in Pharma
2020-01-20 - 2020-01-21 | HOLIDAY INN KENSINGTON FORUM, 97 Cromwell Road, London, SW7 4DN, United Kingdom
The conference aims to bring together experts of emerging technologies to discover the opportunities with regards to Artificial intelligence, Machine Learning, Internet of Things, Digital therapeutics, eHealth and blockchain. The effect of these technologies on the industry will be discussed with the aim to highlight challenges related to the implementation of these new technologies and to discuss how to overcome them.

Industry case studies will reveal personal experiences and strategies to approaching digitalization, providing a benchmark for practice and improving understanding of forecasts until 2020.
Transformations require regulatory adjustments therefore, the conference will also feature insights into new regulatory guidelines and standards of practice, with special focus on the new class of drugs called digital therapeutics, to provide a complete picture of every aspect of the transformation process.
Network and learn from leading professionals such as Vice Presidents, Directors Managers and Heads of: Emerging/Disruptive Technologies, Artificial Intelligence, Machine Learning, Data Science/Analytics, Technology, External and Internal Innovation, Digital IoT and Bioinformatics
CHAIRS FOR 2020:

Karl Hess, Managing Director, OnDigitalHealth Consulting

FEATURED SPEAKERS INCLUDE:

Mark Campbell, Freelance Regulatory Expert, former NICE
Vladimir Anisimov, Principal Data Scientist, Amgen
Joseph Dalton, Global Lead Digital Health Solutions and Medical Outcomes, Novartis

For more information and to register, visit www.disruptivetech-pharma.com/pjwb
Contact Info:
T: +44 (0) 20 7827 6164
E: nhoward@smi-online.co.uk

SMi’s 9th Annual Pharmaceutical Microbiology Conference
2020-01-20 - 2020-01-21 | Copthorne Tara Hotel, London, UK, United Kingdom
SPONSORED BY
Associates of Cape Cod, bioMérieux, COPAN, METTLER TOLEDO, Microgenetics, Reading Scientific Services Limited, Veltek Associates
CHAIRED BY
James Drinkwater, Chairman, Pharmaceutical and Healthcare Science Society
Olivier Chancel, Sterility and Aseptic Practices Expert, Boehringer Ingelheim
Discovering optimised contamination control and the current regulatory landscape
Pharmaceutical Microbiology as an industry is projected to see significant advancements in the next five years. This forecast is largely attributed to rapid microbiology testing, which has accounted for $3.5 billion last year, while projected to reach nearly double at $6 billion by 2025, and an estimated CAGR of 8.3% leading up to 2025.
At the very core of pharmaceutical microbiology is the accurate and reliable detection of microorganisms that would otherwise contaminate the pharmaceutical products manufactured. This demand for more rapid methods for detection and identification will be accompanied by equally important areas such as: contamination control strategies and environmental monitoring, process automation, and discussing updates to meet regulatory requirements.
Join us at SMi’s 9th Annual Pharmaceutical Microbiology Conference to explore novel and developing technologies that tackle the most pressing challenges and push innovation in world of pharmaceutical microbiology.
Event Hashtag: #SMiPharmaMicroUK
At the 9th Annual Pharmaceutical Microbiology Conference, you will gain insight into:
FEATURED SPEAKERS INCLUDE:

Luis Meirinhos-Soares, GMP Inspector,Infarmed IP
Jim Polarine, Senior Technical Service Manager,STERIS Corporation
Tim Eaton, Sterile Manufacturing Specialist,AstraZeneca
Pratixa Patel, Senior Director,Microbiology and Stability Sciences, GSK
Ian Symonds, Pharmaceutical Consultant, SDA Pharma
Michael Song, Senior Manager,MedImmune
Maria Jose Zafra-Domene, Microbiology QC Team Leader,MeiraGTx
Ingo Spreitzer, Deputy Head Section Microbial Safety,Paul Ehrlich Institute

KEY HIGHLIGHTS INCLUDE FOR 2020

Discuss the regulatory expectations and supportive guidance on bio-contamination control and monitoring in aseptic manufacturing of sterile products fromPHSS
Gain valuable insight from key opinion leaders in a panel discussion on the impact of the Annex 1revisions on pharmaceutical microbiology
Examine the common myths and urban legends in the pharmaceutical industry related to contamination control from STERIS
Explore container closure integrity and controls strategies ensuring product sterility from AstraZeneca
Revisit the role of the Official Medicines Control Laboratories as the GMP back up from Infarmed IP

View the full agenda: www.pharma-microbiology.com/PJwl
WHO SHOULD ATTEND?
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist Drug Substance External Manufacturer, Business Development Manager – Testing, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist
EARLY BIRD-RATES

BOOK BY 30TH SEPTEMBER AND SAVE £400
BOOK BY 31ST OCTOBER AND SAVE £200
BOOK BY 29TH NOVEMBER AND SAVE £100

Temperature Control and Logistics
2020-01-27 - 2020-01-30 | Crowne Plaza Dusseldorf – Neuss, Dusseldorf
The Temperature Control and Logistics forum remains the industries foremost operational and hands on conference to discuss everything logistics, supply chain and temperature controlled for the Pharmaceutical Industry.

Our vision for 2020 is to ensure that we remain true to our role in the industry – building a network of world leading expert speakers and facilitators alongside the industries leading solution providers and attendees to address how we can work together to practically advance the industry past the biggest and current hurdles and challenges. We are committed to ensuring that we help every single delegate, industry partner and expert speaker to achieve their unifying goal: Transforming the industries current capabilities by optimising global logistics and supply chain processes to better serve the patient populations at the heart of the conversation.
Across four days of workshops, keynote presentations, case studies, interactive think tank discussions and networking – we will ensure that the industry leaves with the strategies, solutions and partners to overcome their most pressing operational challenges in order to make industry transformation and – patient care – possible.
To learn more about Temperature Control and Logistics visit http://bit.ly/2mRcY8I

Commercializing Continuous Processing in Pharma (CCP)
2020-01-28 - 2020-01-30 | The Colonnade, 120 Huntington Avenue, Boston, MA, United States
The CCP Summit 2020 is the only dedicated community for continuous manufacturing commercialization in Pharma.
Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting.
Over the last 12 months we have seen major milestones in continuous manufacturing globally – PROSPECT project in the UK, GSK’s announcement of CM facilities in Singapore, Merck has filed an NDA under CM approach, Bill & Melinda Gates Foundation granted $14.3m to Univercells to deploy CM for measles and rubella vaccine continuous manufacturing.
At the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’.
This is the one and only CCP meeting bringing together small molecules and biologics experts under one roof for knowledge and experience exchange!
Join us in Boston for the 4th time on Jan 28 – 30, 2020. Find out more about the CCP Summit > https://ter.li/9slw1t

Parallel Trade 2020
2020-02-04 - 2020-02-05 | Holiday Inn, Kensington Forum 97 Cromwell Rd, Kensington, London SW7 4DN, United Kingdom
Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
SMi presents Europe’s leading 14th annual Parallel Trade conference, taking place in London on the 4th-5th of February 2020. As the only B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.
The size of the EU market in pharmaceutical distribution is around €5bn, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn, while the annual export figure approximates £600m.
The 2020 event will hold a particular place of significance on shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights.
Furthermore, the FMD (Falsified Medicines Directive) will be coming into effect in February 2020. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market.
The benefits of attending:
This conference is a must-attend show for anyone involved in the parallel trade industry within pharmaceuticals and life sciences. Attending the show gives you the chance to interact with and discuss common issues with leaders involved in all the areas of the parallel trade industry. Furthermore, this provides core information to further strengthen your industry knowledge and approaches.

Assessing the economic impact and dynamics of Parallel Trade
Reviewing how to overcome the challenges and hurdles in Parallel Trade
Understanding the underlying principles of the EU internal market and competition policies
Discussing the impact of Parallel trade on patient safety
What’s the impact and consequences of a no deal Brexit on testing and clinical trials?
Impact on shortages, availability, accessibility and innovation
Assessing current EU legislative instruments and changes in IP framework
An update on current illegal trade cases and the Falsified Medicines Directive

EARLY-BIRD RATES:

BOOK BY 31st OCTOBER AND SAVE £400
BOOK BY 29th NOVEMBER AND SAVE £200
BOOK BY 13th DECEMBER AND SAVE £100

Plus two pre-conference interactive workshops
Workshop A : Parallel Trade and Brexit… Where are we now?
Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd
Workshop B: Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade
John Schmidt, Partner, Antitrust, Arnold & Porter Kaye Scholer
Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
LinkedIn: @SMi Pharma
Twitter: @SMiPharm #SMi #SMiParallel

Smartlab Exchange USA
2020-02-04 - 2020-02-05 | Hilton Fort Lauderdale Marina, FL, United States
The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across the world, plus a number of hand-selected solution providers for two days of one-to-one business meetings, benchmarking, discussions and networking.

Key themes include:
✓ Devising a Roadmap to Success for an Agile, Adaptable, Digitized Lab
✓ Harnessing Lab Automation Strategies
✓ Leverage Big Data Analytics and Informatics
✓ Augmenting Existing Systems/Processes with Emerging Technologies
✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance
96% of our attendees would recommend our event
“I got more out of one day at Smartlab than a normal day at another conference.” – R&D IS Program Manager, Biomerieux
Below are some of the 20+ presentations and interactive sessions we have in store:

Abbvie – Transforming The R&D Lab: What It Takes
IDC – Leveraging AI To Supercharge Data and Analysis Efficiencies In The Connected Lab
Pepsico – Blending Technology, Process and Digitization To Enable Smart Data-Driven Lab Transformation
Johnson & Johnson – The Digital Patient & Consumer In Healthcare

Check out the full agenda here: http://bit.ly/35z1F5m

4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference
2020-02-06 - 2020-02-07 | San Diego, CA
Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool, gene expression, knock-in, genomic screening, along with therapeutic developments through animal modeling. Attended by 100+ genome editing professionals and 20+ gene expert speakers, the event saw participation of big companies like Casebia Therapeutics, Genentech, BMS, Cellectis , University of Laval, University of California, Center of Advanced Genome Engineering, Georgia Tech, Stanford University, Locana, Harvard Medical School, Agility, Poseida, Vertex, Ligandal, Integrated DNA Technologies, GE Healthcare, Cellecta, Agilent, Advanced Analytical, Thermofisher, Atum, Synthego, New England Biolabs, Aldevron, Applied Stem Cell and more.

In 2020, coming with the 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference on 6th & 7th February in San Diego, we are getting ahead by discussing the commercialization and advancements of technology which will outline breakthrough advancements in pre-clinical & clinical therapeutics using genome Editing. The event will also focus on analysis of off target effects, specificity and aspects of gene and cellular therapies.
To learn more about 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference click here

5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
2020-02-06 - 2020-02-07
The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th – 7th February 2020 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

To learn more about 5th Annual Biomarker and Companion Diagnostics Conference click here

MarketsandMarkets Gen-Next Probiotics and Microbiome Congress
2020-02-06 - 2020-02-07 | San Diego, CA
What are the essentials being missed out on? What is the real role of probiotics strains, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis?
Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.

Join us at Gen-Next Probiotics and Microbiome Congress, 2020 to network with biotech, pharma, academicians and investors to exchange views and observe the most ingenious research and technologies. Understand what’s happening. Witness the amalgamation of study focused on pharmaceutical and medicinal approaches of probiotics and the nutraceutical and consumer approaches along with the role of microbiome in clinical applications and preventative medicine.
To learn more about MarketsandMarkets Gen-Next Probiotics and Microbiome Congress click here

Smartlab Exchange Europe
2020-02-17 - 2020-02-18 | Hotel Palace Berlin, Germany
The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across Europe, plus a number of hand-selected solution providers for two days of one-to-one business meetings, benchmarking, discussions and networking.

Key themes include:
✓ Devising a Roadmap to Success for an Agile, Adaptable, Digitised Lab
✓ Leveraging Big Data Analytics and Informatics
✓ Embedding a Culture of Collaboration and Innovation
✓ Enhancing Visibility Across Existing Systems/Processes and Integrate Emerging Technologies
✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance
96% of our attendees would recommend our event
“I got more out of one day at Smartlab than a normal day at another conference.” – R&D IS Program Manager, Biomerieux
Below are some of the 20+ presentations and interactive sessions we have in store:

Novartis – Exploring Data Visualisation Software To Increase The Accuracy Of Your Predictions
Roche – Connecting Your Instruments For Easy Data Access And Analysis Across Your Lab
Janssen – The Lab Of The Future: Predicting How The Lab Will Develop In the Next 5 Years
UCB – Developing Your Data Capture Process For Increased Efficiency

Check out the full agenda here: http://bit.ly/2T75ps7

Disposable Solutions for Bio Manufacturing
2020-02-18 - 2020-02-20 | Leonardo Royal Hotel Berlin Alexanderplatz, Berlin, Germany, Germany
Now in it’s 12th year, the 2020 Disposable Solutions for Biomanufacturing Forum is the only global forum that focuses on the use of disposable products and single use systems in biomanufacturing. Our attendees will be guided through their journey and understand how they can run 100% disposable sites and scale their manufacturing capabilities with our newly designed program focused on implementation, systems management and future technology.

The three packed days will consist of case studies and interactive sessions to identify new technologies, determine how to approach automated systems, transition to continuous processes and learn how to implement best practice in system testing & life cycle management!
To learn more about Disposable Solutions for Bio Manufacturing and to register online, visit http://bit.ly/2Mp6lEs

RNA Therapeutics
2020-02-19 - 2020-02-20 | London, UK, United Kingdom
SMi Group are pleased to present the 11th Annual RNA Therapeutics Conference and Focus Day in London on February 18th – 20th 2020.
The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

The event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore, for the first time in the series, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination.
NEW FOR 2020: RNA Therapeutics Focus Day – Oligonucleotide Delivery Systems
Introducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025, projected to reach $1.81 billion, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today’s market.
How will you benefit?

Discuss the innovations in oligonucleotide delivery systems
Explore the latest developments in RNA delivery agents and RNA-based therapeutics
Learn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies
Revisit the challenges for clinical translation of RNA-based therapeutics
Evaluate the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing
Gain an expert view on new and upcoming regulatory updates and industry implications

Network and learn from leading professionals such as:
CHAIR FOR 2020
Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech
FEATURED SPEAKERS INCLUDE:

Shalini Andersson, Chief Scientist New Therapeutic Modalities, AstraZeneca
Christian Plank, CTO, Ethris
Steve Pascolo, Founder and CEO, Miescher Pharma
Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MhRA
Steven Powell, CEO, eTheRNA
Simon Newman, CSO, Nanogenics
Christiane Niederlaender, Director, AMBR Consulting and Formerly,
Quality Assessor, Biologicals, MhRA
Klaus Giese, CEO, Pantherna Therapeutics
David Blakey, CSO, MiNA Therapeutics
Jeffrey Ulmer, Head Preclinical R&D, GSK

For more information and to register, visit: www.therapeutics-rna.com/pjwb
Early-Bird Rates
REGISTER BY 31ST OCTOBER TO SAVE £400
REGISTER BY 29Th NOVEMBER TO SAVE £200
REGISTER BY 13Th DECEMBER TO SAVE £100
Social Media Handles
Follow us on LinkedIn ‘SMi Pharma’, Twitter @SMiPharm and use #SMiRNA

SMi’s 4th Annual 3D Cell Culture
2020-02-19 - 2020-02-20 | Copthorne Tara Hotel, London, UK, United Kingdom
CHAIRED BY:
Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
Stefan Przyborski, Professor of Cell Technology, Durham university
Development and application of human organs and tissues in vitro
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

SMi’s 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.
Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.
For the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma, biotech’s and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy, drug screening and extracellular matrix scaffolds.
Event Hashtag: #SMi3DCellCulture
FEATURED SPEAKERS INCLUDE:

Leonard Both, Senior Quality Assessor, Biologicals/Biotechnology Unit, MHRA
Veronique Barban, Expert Virology, Research and Nonclinical Safety Department, Sanofi Pasteur
Simone Stahl, Associate Principal Scientist, ADME Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca
Wendy Rowan, Scientific Director, Novel Human Genetics Research Unit, GSK
Jason Ekert, Head of Complex In Vitro Models, GSK
Samuel Jackson, Programme Manager, Disease Models Efficacy and Safety Pharmacology, NC3RS

KEY TOPICS FOR 2019 INCLUDE:

Learn from leading pharma companies to benchmark against their applications of 3D technology
Explore case studies of 3D cell culture, high throughput screening, imaging and microphysiological systems in industry
Hear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models
Discuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research
Participate in a panel discussion on adopting new technologies for 3D models

View the full agenda: http://www.3d-cellculture.com/PJWL
WHO SHOULD ATTEND?
Biotech / Pharma Companies – Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer
EARLY BIRD-RATES

REGISTER BY 31ST OCTOBER AND SAVE £400
REGISTER BY 29TH NOVEMBER AND SAVE £200
REGISTER BY 13TH DECEMBER AND SAVE £100

CAR-TCR Europe Summit
2020-02-24 - 2020-02-27 | Novotel London West, Hammersmith, London, W6 8DR
With CAR-T therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for. The CAR-TCR Europe Summit will unravel the technical challenges across translation, scale and delivery to provide your team with the platform to learn, collaborate and gain actionable insights to advance your therapy for clinical and commercial success.
This focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle, providing a comprehensive analysis across 3 tracks including: Translational, Manufacturing & Clinical
To learn more about CAR-TCR Europe Summit and to register online, visit https://ter.li/9iuqer

3rd Antigen Specific Immune Tolerance Summit
2020-02-25 - 2020-02-27 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116
Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications
Accelerate the progression of ethical and effective antigen specific immunotherapies through the clinic, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies.

Building on the success of the 2019 meeting, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27, 2020. The meeting will bring together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.

Hear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk, Pfizer, Merck, Eli Lilly, ITN & FDA
Explore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction
Engage with and immerse yourself within a learning journey across three conference days, tackling all elements of drug development from discovery to clinical development
Gain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials
Employ novel therapeutics in combination with antigen specific immunotherapies and drive the progression of drug development towards the clinic
Take advantage of intimate networking opportunities with key opinion leaders from large pharma, biotech and academia through discursive and engaging platforms that spark conversation and debate

To learn more about 3rd Antigen Specific Immune Tolerance Summit and to register online, visit https://ter.li/rp07a3

RAS- Targeted Drug Discovery Summit Europe
2020-02-25 - 2020-02-27 | Hilton Vienna Plaza, Schottenring 11, Vienna, A - 1010, Austria
After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins.

The RAS- Targeted Drug Discovery Summit Europe is the only industry-led and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. Hear from the likes of Boehringer Ingelheim, Sanofi, Bayer, Francis Crick Institute, PhoreMost, Allinky Biopharma, Elicio Therapeutics, Oblique Therapeutics, Onconova Therapeutics and Revolution Medicines. Visit the website to see the full speaker line-up, what will be discussed, pricing and ticket options: https://ter.li/8qb2rr.

8th Neurodegenerative Drug Development Summit
2020-02-25 - 2020-02-27 | Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, MA, 02111, United States
Returning to Boston in February 2020 is the 8th Neurodegenerative Drug Development Summit, previously World CNS.
Despite the lack of clinical trial success, new investments are being made in forward-thinking biotechs, digital and blood-based biomarker technologies are advancing, new targets are emerging, and gene therapy is taking the limelight.
The Neurodegenerative Drug Development Summit will unite industry stakeholders to learn how to overcome their translational challenges, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics.
Don’t miss your opportunity to join over 150 fellow CNS experts from Biogen, AbbVie, Sanofi and more, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.

21st Pharmacovigilance 2020
2020-02-26 - 2020-02-27 | Pestana Chelsea Bridge Hotel, London, United Kingdom
“Latest developments in pharmacovigilance, drug safety and RMP”
21st Pharmacovigilance 2020 event keeps an immersed eye on discussion of critical topics in PV domain, which capture influence of emerging technologies like AI, IoT, Big Data. Not merely that, we have exciting surprise activities which will help you to interact more with your peers. This will be surely an exciting event wherein you could get chance to meet big industry gems. Let’s gather to shape the industry with your magnificent ideas.

SPONSORS:

Covance
Brookwood Global

We also have more sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit/Booth/Stall and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts.
DELEGATE REGISTRATION:
In order to register please contact us on Email: kavitha@virtueinsight.co.in
1 Delegate @ £1299 + VAT
3 Delegates @ £2598 + VAT
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Animal Microbiome & Nutritional Health Congress
2020-03-03 - 2020-03-04 | Warwick Allerton – Chicago, 701 N Michigan Avenue, Chicago, IL, 60611, United States
Building on the huge success of our European Animal Microbiome Congress in London this past July, we are incredibly excited to return to the USA in March 2020, this time in Chicago, Illinois.

Interest in animal microbiomes as therapeutics is rapidly expanding, as techniques to study the microbial world decrease in cost and increase in accessibility, and case studies from human medicine receive widespread attention. The current state of techniques and strategies to modify the microbiome to improve animal health, focusing on applications in domestic pets and farm animals, will be the main focus of this event.
We will be untangling the basic biology of microbiome-directed therapies in animals and the examples to date of application of probiotics, prebiotics, and other microbiome-directed therapies and feed additives being used to benefit animal health. We will also be looking heavily at the impact of different feed and nutrition profiles on animal microbiomes, and the power of nutrition in affecting animal health in a beneficial way.
Finally, the event will host the Animal Microbiome & Nutritional Health Innovation Showcase, where 8 emerging companies in the field of animal nutrition will present the microbiome and nutritional solutions they can bring to market.
To learn more about this event and to register online, visit https://animalmicrobiomecongressusa.com/

Gene Therapy for Blood Disorders
2020-03-03 - 2020-03-05 | Courtyard Boston Downtown, 275 Tremont Street, Boston, MA, 02116, United States
Discover the Clinical & Commercial Potential of Gene Therapy & Editing Approaches Revolutionizing Hemophilia, Sickle Cell Disease & β-Thalassemia Treatment
Revolutionary gene therapies are redefining the treatment of blood diseases.

With an approved gene therapy treatment for β-thalassemia in the EU, and hemophilia candidates seeking 2020 approval in the USA and beyond, pioneers in the space must overcome hurdles they have never previously encountered to transform their clinical candidates into a commercial reality. Gene Therapy for Blood Disorders will unite industry leaders across the blood disease space to delve into the specific clinical and commercial challenges faced by companies developing gene therapies for hemophilia, sickle cell disease and
β-thalassemia.
Evaluate the best strategies for a commercial launch in blood disease, optimize your trial design, gain insights on revolutionary novel technologies, and ultimately enhance your current hematology gene therapy program to bring transformative treatments to patients more quickly and efficiently.
Download the full event guide to learn more from companies including bluebird bio, Spark Therapeutics and Editas Medicine

8th Annual Pharma AntiCounterfeiting & Serialisation 2020
2020-03-04 - 2020-03-05 | Pestana Chelsea Bridge Hotel, London, United Kingdom
8th Annual Pharma AntiCounterfeiting & Serialisation 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI, IoT and blockchain within pharma and healthcare through a mixture of practical, lectures and roundtable discussions specifically designed.
CONFERENCE SPONSORS:

IO AG

We have sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in
CONFERENCE DELEGATE PRICING:
In order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.

Early Bird Discount Price:
1 Delegate @ £899 + VAT (Valid Till 24th Jan 2020)
3 Delegates @ £1798 + VAT (Valid Till 25th Jan 2020)
Standard Price:
1 Delegate @ £1299 + VAT (Valid from 25th Jan 2020)
3 Delegates @ £2598 + VAT (Valid from 25th Jan 2020)
KEY SPEAKERS:

NICHOLAS CALL, Special Agent, FDA
GALIT MEYRAN, Serialization Global Program Manager, Teva
MARCEL DE GRUTTER , Project Manager Serialization – Regulatory & Government Affairs Liaison, Abbott
PATRIK MERCKELL, External Business Process Analyst and Project Manager, Roche
EIKE HILLBRICHT , Corporate Security Manager, Boehringer Ingelheim
JACK JING , Global Business Development Director / Head of EU Commercial Operations, Seacross Pharmaceuticals
LEYLA HANNBECK , CEO, Association of Independent Multiple Pharmacies
SULTAN DAJANI , Pharmacist Superintendent, Wainwrights Chemists
TRACQ ANTOINE, Head of Commercial Logistics & Serialization, Galderma
ADRIAN VAN DEN HOVEN, Director General of Medicines for Europe, European Medicines Verification Organisation (EMVO)
MIKE ISLES, Executive Director, European Alliance for Access to Safe Medicines
MONIKA DERECQUE POIS, Director General, GIRP—European Healthcare Distribution Association
BILL ARONSON , COO, Artificial Intelligence Research Group
MARIE MANLEY , Partner, Head of the UK Life Sciences Practice, Sidley Austin
SANDY EISEN, Chief Medical Officer, Fromtline Pharma

Plus many more
KEY THEMES:
Anti-counterfeiting, Serialisation, T&T

Shaping the future for Healthcare
Effect of Post (FMD) Deadline
Serialisation strategies- Choosing a Serialisation solution
AI algorithms to crack down on fake products
Fight the FAKE – Protect the public
Technology Impact – Current digital world
Serialisation and Compliance
Penetrating the legitimate supply chain
Packaging Techniques – Protecting your products

Brexit

Impact on EU, US and Row market

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

3rd Annual Phrama AI, IoT & Blockchain 2020
2020-03-04 - 2020-03-05 | Pestana Chelsea Bridge Hotel, London, United Kingdom
“Competences to Combat Counterfeits & Impact of AI, IoT, Blockchain & Big Data in Pharma”
Our 3rd Annual Pharma AI, IoT & Blockchain 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI, IoT and blockchain within pharma and healthcare through a mixture of practical, lectures and roundtable discussions specifically designed.
SPONSORS:

io AG
Advanco

We have more sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in

CONFERENCE DELEGATE PRICING:
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.
In order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in
1 Delegate @ £1299 + VAT
3 Delegates @ £2598 + VAT
KEY SPEAKERS:

STEVEN ABRAHAMSON, Senior Director, Product Cyber Security, GE Healthcare
PATRIC JARCHOW , Head of Global Multi-Channel Strategy, Merck KGaA
NICLAS NILSSON , Head of Open Innovation in Research, LEO Pharma
STEVEN WILLIAMSON, Audit Account Director, Information Security, GSK
EDDIE GUZDAR , Medical Head UK & Ireland | Physician | Venture Capital & Board Advisor – Digital Technology, Sanofi Genzyme
NATALIA M.MONTEIRO, Clinical Trial Budget & Metrics Management, Takeda Pharmaceuticals
PINGPING NI, Director, Biometrics Team Lead, AstraZeneca
ALAN HOW, Strategy & Operations – Global Commercial, Merck
HUSSAIN AL MUSCATI , Customer Engineering Lead, Life Sciences, Google
MARCO GUIDOBALDI , Sales Engineer – Healthcare & Life Sciences, Google
EBERHARD SCHEUER , Chairman, HIT Foundation
GABOR PURMAN , Senior Account Director, Patient Services and Medical Education, NexGen Healthcare Communications
ROMIKA BHOWMICK, Senior Manager – Digital Commercial (Europe & International Markets), Teva
BRAM VAN LEEUWEN , Lead (digital) Innovation BeNeLux, Sanofi
EVI MATHIOU, Legal, Compliance & Quality Manager BA Europe East & South, Novo Nordisk
MYLES FURNACE, Digital Health and Data Lead, UK & Ireland Speciality Care, IPSEN
RAMESH KRISHNAMURTHY , Strengthen international institutions, WHO (World Health Organization)
SIDDHI TRIVEDI , Healthcare Innovator, Co-founder, Beyond Identity
ALF GOEBEL, CEO, Advanco
IGNACIO H. MEDRANO, Founder & Chief Medical Officer, SAVANA
EDITH LECOMTE NORRANT , CEO & CSO, IPSOMEDIC
ROBIN SMITH, Security and Information Assurance Lead, Independent Office for Police Conduct (IOPC)

Plus many more
KEY THEMES:
AI and IoT

Applications in Pharma and Healthcare
Challenges and opportunities
Use of AI in drug discovery
Role of Cyber Security in age of IoT and Healthcare Hacks
IP – Cybercrime in the pharmaceutical industry: a booming business
Transforming the healthcare and pharmaceutical industry

Blockchain

How it transforms pharma and healthcare
Blockchain in Logistics and Supply Chain
A must learn technology
Blockchain technology and start-ups – where do you get started?
Application areas for blockchain within healthcare?

Big Data

Potential future in synchronicity of data
Big data =Big impact
A Revolution in Drug Discovery and Pharma R&D
How to involve patients better to develop drugs

Brexit

Impact on EU, US and Row market

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Inborn Errors of Metabolism Drug Development
2020-03-10 - 2020-03-12 | Courtyard Boston Downtown/North Station, 107 Beverly Street, Boston, MA, 02114, United States
Join over 80 inherited metabolic disease drug developers and KOLs to explore how the key challenges prohibiting accelerated drug development are being addressed. The inaugural Inborn Errors of Metabolism Drug Development Summit will provide a discursive platform to examine where pioneering gene therapy modalities intersect with current therapeutic options and explore how diseases can be better targeted in order to address the huge unmet medical need for rare metabolic diseases.
With scarce treatment options leaving inborn errors of metabolism a devastating, unfilled and unmet medical need, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy, safety and commercial viability.
Incorporating insights from industry-leading speakers, this conference will delve into the key patient access, regulatory, clinical and commercial hurdles that need to be overcome in order to address the unmet medical need of rare metabolic diseases and fulfil their full commercial potential.
This is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism.
To know more about Inborn Errors of Metabolism Drug Development please click here.

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
2020-03-12 - 2020-03-13 | ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD
In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
Key Sessions:

Updates in development of monoclonal antibodies, ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)
Biomarkers and Cancer Vaccines
CAR-T cell therapy, T Cell Therapy
Tumor microenvironment
Oncolytic Viruses
Microbiome in Cancer Immunotherapy

To learn more about 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress click here

AI in Drug Discovery Conference 2020
2020-03-16 - 2020-03-17 | London, United Kingdom
Leveraging machine learning – discovery to the next level!
SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020.
AI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR, AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
The presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning, neural networks and natural language processing. However, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms.

BENEFITS OF ATTENDING:

Listen to case studies form industry leader pharmaceutical and biotechnology that have already incorporated AI into their work
Explore how Deep Learning Methods can be leveraged for compound screening, de novo design, multiparameter optimization/ ADME toxicity property predictions, chemical synthesis route predictions
Discover strategies for overcoming data-related challenges such as lack of consistent and quality data at the heart of AI and strategies for improving data access
Define unique discovery approaches such as fragment-based drug discovery and network-driven drug discovery

Join us at SMi’s inaugural AI in Drug Discovery 2020 Conference and explore the latest AI-enabled approaches for lead compound screening, multi parameter optimization, disease modelling, drug synthesis and design.
To register please visit: www.AI-indrugdiscovery.com/pharmajwl
PLUS, one interactive half-day post-conference workshop
Practical application of predictive properties in drug design, Workshop Leader: Robert Young, Blue Burgundy Ltd.
Early-Bird Rates

BOOK BY 29TH NOVEMBER AND SAVE £400
BOOK BY 13TH DECEMBER AND SAVE £200
BOOK BY 31ST JANUARY AND SAVE £100

SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #SMiDrugdiscovery
LinkedIn: follow our company page – search ‘SMi Pharma’
